The growing interest in effective weight management has resulted in considerable research into cutting-edge treatments. Lately , Retatrutide, a combined -action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor stimulator, has shown promising results in clinical trials, indicating potential for consider